Trial NCT00849667

View at ClinicalTrials.gov 
Org. Study IDs: MORAb003-004
Secondary IDs: 2008-005872-29

Last trial update was posted on 2022-12-30

MeSH Interventions

Carboplatin Farletuzumab Taxane

MeSH Conditions

Carcinoma, Ovarian Epithelial Hypersensitivity Ovarian Neoplasms

Other Conditions

Ovarian Cancer

Stopping Reasons

Lack of efficacy

Limitations And Caveats

Study termination was based on the primary analysis results for progression-free survival (PFS). Data collection and analyses of health care resource utilization were not performed due to the study being terminated early. Pharmacokinetic data was collected and analyzed for a maximum of only 7 participants in this study.

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID